Susan M. O’Brien, MD of University of California Irvine discusses how to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Advertisement